Clinuvel Pharmaceuticals (ASX: CUV) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Clinuvel Pharmaceuticals Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Clinuvel Pharmaceuticals (ASX: CUV)
Latest News
Share Market News
ASX 200 lunch time report: ANZ, Appen, & Speedcast higher
Share Market News
ASX 200 lunch time report: CBA & Nearmap lower, Afterpay higher
Share Gainers
ALL ORDINARIES finishes lower Tuesday: 8 ASX shares you missed
Share Market News
ASX 200 lunch time report: ANZ, Northern Star, & Webjet shares higher
Share Market News
ASX 200 lunch time report: ANZ, Altium, & Brickworks higher
Share Market News
Leading fundie names 2 bargain small-cap picks
Share Gainers
ALL ORDINARIES finishes higher Tuesday: 8 ASX shares you missed
Share Market News
ASX 200 lunch time report: Appen & WiseTech Global lower, NAB higher
Share Fallers
Why Bravura, Clinuvel, CSR, & Medibank shares tumbled lower today
Share Market News
3 ASX results you might have missed: Australian Ethical, Cedar Woods, & CLINUVEL
Share Fallers
These were the worst-performing shares on the ASX 200 last week
⏸️ Investing
Is the Clinuvel share price in the buy zone?
Frequently Asked Questions
-
Yes, Clinuvel Pharmaceuticals has historically paid one unfranked shareholder dividend a year.
-
Clinuvel Pharmaceuticals generally pays its shareholder dividend in September.
-
Clinuvel Pharmaceuticals does not have a dividend reinvestment plan.
-
Clinuvel Pharmaceuticals Limited listed on the ASX on 13 February 2001.
CUV ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Clinuvel Pharmaceuticals
Clinuvel Pharmaceuticals Ltd (ASX: CUV) is an Australian-based global biopharmaceutical company developing drugs for the treatment of genetic and vascular disorders. Its principal product SCENESSE is a drug for an inherited disorder, erythropoietic protoporphyria, that causes an intolerance to light.
Its pioneering work aims at preventing the symptoms of skin diseases related to exposure to UV radiation and at repigmentation of the skin due to depigmentation disorders. Geographically, the company derives the majority of its revenue from its US and European markets.
